ESMO 2023 | Assessing cognitive impairment: crucial considerations in treatment planning

Daniele Raggi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, emphasizes the importance of assessing cognitive function before initiating cancer treatment, particularly in cases with limited time. This baseline evaluation is crucial for medical oncologists, allowing them to understand the patient’s cognitive status and make informed decisions throughout the treatment course. Dr Raggi highlights its significance in selecting appropriate drugs, especially novel hormonal agents, considering their toxic profiles. Monitoring cognitive function enables adjustments in dosage, treatment schedules, and strategic pauses, contributing not only to the patient’s quality of life but also ensuring better compliance with prescribed medications. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.